The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa.

The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa.

There is an urgent need to improve the evidence base for provision of second-line antiretroviral therapy (ART) following first-line virological failure. This is particularly the case in Sub-Saharan Africa where 70% of all people living with HIV/AIDS (PHA) reside. The aim of this study was to simulat...

Full description

Bibliographic Details
Main Authors: Karen Schneider, Chidi Nwizu, Richard Kaplan, Jonathan Anderson, David P Wilson, Sean Emery, David A Cooper, Mark A Boyd
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3574122?pdf=render

Internet

http://europepmc.org/articles/PMC3574122?pdf=render

Similar Items